Last reviewed · How we verify
Ticagrelor loading dose
Ticagrelor is a P2Y12 platelet receptor antagonist that irreversibly blocks ADP-induced platelet aggregation to prevent thrombotic events.
Ticagrelor is a P2Y12 platelet receptor antagonist that irreversibly blocks ADP-induced platelet aggregation to prevent thrombotic events. Used for Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis, Chronic coronary syndrome for secondary prevention of cardiovascular events.
At a glance
| Generic name | Ticagrelor loading dose |
|---|---|
| Also known as | Brilinta |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Drug class | P2Y12 platelet receptor antagonist |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelets, inhibiting platelet activation and aggregation. The loading dose (typically 180 mg) rapidly achieves therapeutic platelet inhibition, reducing the risk of stent thrombosis and recurrent cardiovascular events in acute coronary syndrome patients. This mechanism is distinct from clopidogrel as ticagrelor does not require hepatic metabolism for activation.
Approved indications
- Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis
- Chronic coronary syndrome for secondary prevention of cardiovascular events
Common side effects
- Bradycardia
- Dyspnea
- Bleeding (major)
- Ventricular pauses
- Hyperuricemia
Key clinical trials
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE (PHASE3)
- Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA (PHASE3)
- The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin (PHASE4)
- Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA (PHASE3)
- Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor loading dose CI brief — competitive landscape report
- Ticagrelor loading dose updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI